Skip to main content

Articles

Page 2 of 83

  1. Perineural invasion (PNI) is a hallmark feature of pancreatic ductal adenocarcinoma (PDAC), which occurs at a high incidence and significantly contributes to PDAC lethality and poor survival. Despite its preva...

    Authors: Leyi Huang, Yanan Lu, Rihua He, Xiaofeng Guo, Jiajia Zhou, Zhiqiang Fu, Jingwen Li, Jianping Liu, Rufu Chen, Yu Zhou and Quanbo Zhou
    Citation: Journal of Experimental & Clinical Cancer Research 2025 44:103
    Content type: Research Published on:

  2. Circulating tumor cells (CTCs) are pivotal in cancer progression, and in vitro CTC models are crucial for understanding their biological mechanisms. This study focused on the characterization of extracellular ...

    Authors: Luis Enrique Cortés-Hernández, Zahra Eslami-S, Aurore Attina, Silvia Batista, Laure Cayrefourcq, Jérôme Vialeret, Dolores Di Vizio, Christophe Hirtz, Bruno Costa-Silva and Catherine Alix-Panabières
    Citation: Journal of Experimental & Clinical Cancer Research 2025 44:102
    Content type: Research Published on:

    The Correction to this article has been published in Journal of Experimental & Clinical Cancer Research 2025 44:115

  4. Altered metabolism is one of the cancer hallmarks. The role of circRNAs in cancer metabolism is poorly studied. Specifically, the impact of circPVT1, a well-known oncogenic circRNA on triple negative breast ca...

    Authors: Alina Catalina Palcau, Claudio Pulito, Valentina De Pascale, Luca Casadei, Mariacristina Valerio, Andrea Sacconi, Valeria Canu, Daniela Rutigliano, Sara Donzelli, Federica Lo Sardo, Francesca Romana Auciello, Fulvia Pimpinelli, Paola Muti, Claudio Botti, Sabrina Strano and Giovanni Blandino
    Citation: Journal of Experimental & Clinical Cancer Research 2025 44:100
    Content type: Research Published on:

  5. Glioma stem-like cells (GSCs) are key drivers of treatment resistance and recurrence in glioblastoma (GBM). Phosphoglycerate dehydrogenase (PHGDH), a crucial enzyme in the de novo serine synthesis pathway (SSP...

    Authors: Xiaojin Liu, Bangxin Liu, Junwen Wang, Hongbin Liu, Jiasheng Wu, Yiwei Qi, Yuan Liu, Hongtao Zhu, Chaoxi Li, Liu Yang, Jian Song, Guojie Yao, Weidong Tian, Kai Zhao, Lin Han, Kai Shu…
    Citation: Journal of Experimental & Clinical Cancer Research 2025 44:99
    Content type: Research Published on:

  6. In the last two decades, novel and promising cell-based therapies have populated the treatment landscape for haematological tumors. However, commonly exploited T and NK cell-based therapies show limited applic...

    Authors: Daisy Bhatia, Riccardo Dolcetti and Roberta Mazzieri
    Citation: Journal of Experimental & Clinical Cancer Research 2025 44:98
    Content type: Review Published on:

  7. Oncolytic adenoviruses are among the most widely utilized oncolytic viruses due to their notable anti-tumor and gene expression capabilities, and modification of ADVs to create armed adenoviruses remains a pop...

    Authors: Shuo Wang, Lingkai Kong, Linpei Wang, Yan Zhuang, Ciliang Guo, Yuxin Zhang, Huawei Cui, Xiaosong Gu, Junhua Wu and Chunping Jiang
    Citation: Journal of Experimental & Clinical Cancer Research 2025 44:97
    Content type: Research Published on:

  8. Breast cancer ranks as the most prevalent form of cancer globally. Currently, advanced screening methods have significantly improved early detection rates. These achievements have led to more non-invasive canc...

    Authors: Giorgia Scafetta, Gian Luca Rampioni Vinciguerra, Simona Giglio, Omar Faruq, Roberto Cirombella, Ilenia Segatto, Francesca Citron, Maria Chiara Mattevi, Elisabetta Di Renzi, Luciano Cascione, Pierluigi Gasparini, Barbara Belletti, Gustavo Baldassarre, Andrea Sacconi, Giovanni Blandino and Andrea Vecchione
    Citation: Journal of Experimental & Clinical Cancer Research 2025 44:96
    Content type: Research Published on:

  9. Brain metastasis significantly contributes to the failure of targeted therapy in patients with epidermal growth factor receptor (EGFR)-mutated lung adenocarcinoma (LUAD). Reduced expression of RNA-binding moti...

    Authors: Gang Xu, Bo An, Ruqiong Wang, Bo Pan, Huiting Hao, Xingmei Ren, Zihan Jing, Weitong Gao, Yajie Li, Yan Jin, Enguang Lin, Lihua Shang, Dexin Jia and Yan Yu
    Citation: Journal of Experimental & Clinical Cancer Research 2025 44:95
    Content type: Research Published on:

  10. Oxaliplatin-based chemotherapy is the first-line treatment for colorectal cancer (CRC). However, oxaliplatin resistance remains a major challenge contributing to treatment failure and poor prognosis. An increa...

    Authors: Xingwu Liu, Shaoming Zhang, Yue An, Boyang Xu, Guanyu Yan and Mingjun Sun
    Citation: Journal of Experimental & Clinical Cancer Research 2025 44:94
    Content type: Research Published on:

  11. In-depth exploration into the dysregulation of lipid metabolism in hepatocellular carcinoma (HCC) has contributed to the development of advanced antitumor strategies. CRSP8 is a critical component of mediator mul...

    Authors: Yuxi Lin, Zhixing Liang, Zhiyan Weng, Xiaofang Liu, Feng Zhang and Yutian Chong
    Citation: Journal of Experimental & Clinical Cancer Research 2025 44:93
    Content type: Research Published on:

  12. Radiotherapy (RT) is an essential treatment for colorectal cancer (CRC), yet the factors influencing radiosensitivity remain unclear. In the quest to enhance the therapeutic efficacy in CRC, the interplay betw...

    Authors: Peiyuan Mu, Shaobo Mo, Xingfeng He, Hui Zhang, Tao Lv, Ruone Xu, Luoxi He, Fan Xia, Shujuan Zhou, Yajie Chen, Yaqi Wang, Lijun Shen, Juefeng Wan, Lili Huang, Weiqing Lu, Xinyue Liang…
    Citation: Journal of Experimental & Clinical Cancer Research 2025 44:92
    Content type: Research Published on:

  13. Active surveillance (AS) offers a viable alternative to surgical intervention for the management of indolent papillary thyroid carcinoma (PTC), helping to minimize the incidence of unnecessary treatment. Howev...

    Authors: Chunmei Li, Pei Wang, Zhizhong Dong, Weihan Cao, Yanjun Su, Jianming Zhang, Shuyan Zhao, Zhiyuan Wang, Zi Lei, Li Shi, Ruochuan Cheng and Wen Liu
    Citation: Journal of Experimental & Clinical Cancer Research 2025 44:91
    Content type: Research Published on:

  14. Emerging evidence has revealed that PKM2 has oncogenic functions independent of its canonical pyruvate kinase activity, serving as a protein kinase that regulates gene expression. However, the mechanism by whi...

    Authors: Qixiang Li, Hongfei Ci, Pengpeng Zhao, Dongjun Yang, Yi Zou, Panhai Chen, Dongliang Wu, Wenbing Shangguan, Wenyang Li, Xingjun Meng, Mengying Xing, Yuzhong Chen, Ming Zhang, Bing Chen, Lingdong Kong, Ke Zen…
    Citation: Journal of Experimental & Clinical Cancer Research 2025 44:90
    Content type: Research Published on:

  15. The identification of molecular features characterizing metastatic disease is a critical area of oncology research, as metastatic foci often exhibit distinct biological behaviors compared to primary tumors. Wh...

    Authors: Giorgio Bertolazzi, Valeria Cancila, Davide Vacca, Beatrice Belmonte, Daniele Lecis, Parsa Sirati Moghaddam, Arianna Di Napoli, Mario Paolo Colombo, Giancarlo Pruneri, Giannino Del Sal, Giorgio Scita, Matteo Fassan, Andrea Vecchione, Silvio Bicciato and Claudio Tripodo
    Citation: Journal of Experimental & Clinical Cancer Research 2025 44:89
    Content type: Commentary Published on:

  16. The αvβ6- and αvβ8-integrins, two cell-adhesion receptors upregulated in many solid tumors, can promote the activation of transforming growth factor-β (TGFβ), a potent immunosuppressive cytokine, by interactin...

    Authors: Anna Maria Gasparri, Arianna Pocaterra, Barbara Colombo, Giulia Taiè, Chiara Gnasso, Alessandro Gori, Federica Pozzi, Andrew Smith, Fulvio Magni, Alessia Ugolini, Matteo Doglio, Maria Chiara Bonini, Anna Mondino, Angelo Corti and Flavio Curnis
    Citation: Journal of Experimental & Clinical Cancer Research 2025 44:88
    Content type: Research Published on:

  17. Outcomes under anti-PD-(L)1 therapy have been variable in advanced non-small cell lung cancer (NSCLC) without reliable predictive biomarkers so far. Targeted next-generation sequencing (NGS) of circulating tum...

    Authors: Florian Janke, Mateo Gasser, Arlou K. Angeles, Anja L. Riediger, Magdalena Görtz, Louise Appenheimer, Astrid K. Laut, Simon Ogrodnik, Sabrina Gerhardt, Albrecht Stenzinger, Marc A. Schneider, Michael Thomas, Petros Christopoulos and Holger Sültmann
    Citation: Journal of Experimental & Clinical Cancer Research 2025 44:87
    Content type: Research Published on:

  18. Chimeric antigen receptors (CARs) are synthetic receptors that reprogram the target specificity and functions of CAR-expressing effector cells. The design of CAR constructs typically includes an extracellular ...

    Authors: Eunbi Yi, Eunbi Lee, Hyo Jin Park, Hyeon Ho Lee, So Hyeon Yun and Hun Sik Kim
    Citation: Journal of Experimental & Clinical Cancer Research 2025 44:86
    Content type: Research Published on:

  19. Head and neck cancers (HNC) represent an extremely heterogeneous group of diseases with a poorly predictable therapy outcome. Patient-derived tumor organoids (PDTO) offer enormous potential for individualized ...

    Authors: Christian Issing, Constantin Menche, Mara Romero Richter, Mohammed H. Mosa, Jens von der Grün, Maximilian Fleischmann, Philipp Thoenissen, Ria Winkelmann, Tahmineh Darvishi, Andreas G. Loth, Shahram Ghanaati, Franz Rödel, Peter J. Wild, Christian H. Brandts, Timo Stöver and Henner F. Farin
    Citation: Journal of Experimental & Clinical Cancer Research 2025 44:85
    Content type: Research Published on:

  20. Immune checkpoint blockade (ICB) inhibits tumor immune escape and has significantly advanced tumor therapy. However, ICB benefits only a minority of patients treated and may lead to many immune-related adverse...

    Authors: Zelin Li, Shuhan Liu, Deyu Liu, Kangping Yang, Jing Xiong and Ziling Fang
    Citation: Journal of Experimental & Clinical Cancer Research 2025 44:84
    Content type: Review Published on:

  21. Osteosarcoma is the most prevalent cancer-related bone disease diagnosed in the pediatric age group. The rapid development of metastatic lesions and resistance to chemotherapy remain major mechanisms responsib...

    Authors: Laura Di Patria, Nadia Habel, Robert Olaso, Romain Fernandes, Catherine Brenner, Bojana Stefanovska and Olivia Fromigue
    Citation: Journal of Experimental & Clinical Cancer Research 2025 44:83
    Content type: Research Published on:

  22. Neuroendocrine neoplasms (NENs) comprise a group of rare tumors originating from neuroendocrine cells, which are present in both endocrine glands and scattered throughout the body. Due to their scarcity and ab...

    Authors: Pablo Mata-Martínez, Lucía Celada, Francisco J. Cueto, Gonzalo Sáenz de Santa María, Jaime Fernández, Verónica Terrón-Arcos, Nuria Valdés, Vanesa García Moreira, María Isabel Enguita del Toro, Eduardo López-Collazo, María-Dolores Chiara and Carlos del Fresno
    Citation: Journal of Experimental & Clinical Cancer Research 2025 44:82
    Content type: Research Published on:

  23. The effect of m5C modification on oncogene mRNAs has been well studied, while little is known about its influence on mRNAs of tumor suppressor genes (TSGs). Early studies showed PTEN, a key TSG, undergoes alterna...

    Authors: Gaichao Zhao, Ruochen liu, Lingjun Ge, Dan Qi, Qishu Wu, Zini Lin, Houji Song, Liping Zhong and Hongjuan Cui
    Citation: Journal of Experimental & Clinical Cancer Research 2025 44:81
    Content type: Research Published on:

  24. The chemotherapy resistance is an awkward challenge in management of bladder cancer (BC). Cancer organoid model is an effective preclinical tumor model that could faithfully represent clinical manifestations a...

    Authors: Yonghao Zhan, Zhenzhen Zhou, Zhaowei Zhu, Lianghao Zhang, Shuanbao Yu, Yuchen Liu and Xuepei Zhang
    Citation: Journal of Experimental & Clinical Cancer Research 2025 44:80
    Content type: Research Published on:

  25. Circulating tumour DNA (ctDNA) represents an increasingly important biomarker for the screening, diagnosis and management of patients in clinical practice in advanced/metastatic disease across multiple cancer ...

    Authors: Nolwen Guigal-Stephan, Brian Lockhart, Tina Moser and Ellen Heitzer
    Citation: Journal of Experimental & Clinical Cancer Research 2025 44:79
    Content type: Review Published on:

  27. Chromosomal instability (CIN) is involved in about 70% of colorectal cancers (CRCs) and is associated with poor prognosis and drug resistance. From a clinical perspective, a better knowledge of these tumour’s ...

    Authors: Federica Papaccio, Manuel Cabeza-Segura, Blanca García-Micó, Francisco Gimeno-Valiente, Sheila Zúñiga-Trejos, Valentina Gambardella, María Fernanda Gutiérrez‐Bravo, Carolina Martinez‐Ciarpaglini, Pilar Rentero‐Garrido, Tania Fleitas, Susana Roselló, Juan Antonio Carbonell-Asins, Marisol Huerta, David Moro-Valdezate, Desamparados Roda, Noelia Tarazona…
    Citation: Journal of Experimental & Clinical Cancer Research 2025 44:77
    Content type: Research Published on:

  29. In non-small cell lung cancer (NSCLC), the rapid advancement of predictive genetic testing of tumors by identifying specific pathogenic driver variants has significantly improved treatment guidance. However, i...

    Authors: Ella A. Eklund, Johanna Svensson, Louise Stauber Näslund, Maria Yhr, Sama I. Sayin, Clotilde Wiel, Levent M. Akyürek, Per Torstensson, Volkan I. Sayin, Andreas Hallqvist, Sukanya Raghavan and Anna Rohlin
    Citation: Journal of Experimental & Clinical Cancer Research 2025 44:75
    Content type: Research Published on:

  30. Tumor resistance represents a major challenge in the current oncology landscape. Asparagine endopeptidase (AEP) overexpression correlates with worse prognosis and reduced overall survival in most human solid t...

    Authors: Macarena Morillo-Huesca, Ignacio G. López-Cepero, Ryan Conesa-Bakkali, Mercedes Tomé, Colin Watts, Pablo Huertas, Gema Moreno-Bueno, Raúl V. Durán and Jonathan Martínez-Fábregas
    Citation: Journal of Experimental & Clinical Cancer Research 2025 44:74
    Content type: Research Published on:

  32. The emergence of targeted therapies and immunotherapy has broadened treatment options for patients with pancreatic ductal adenocarcinoma (PDAC). Despite this, traditional drug selection, predominantly relies o...

    Authors: Peng Li, Minli Huang, Mengyao Li, Gen Li, Yifan Ma, Yong Zhao, Xiaowu Wang, Yongbin Zhang and Changhong Shi
    Citation: Journal of Experimental & Clinical Cancer Research 2025 44:72
    Content type: Research Published on:

  33. This article has been retracted. Please see the Retraction Notice for more detail: https://doiorg.publicaciones.saludcastillayleon.es/10.1186/s13046-017-0607-0.

    Authors: Shanyang He, Gang Niu, Jianhong Shang, Yalan Deng, Zhiyong Wan, Cai Zhang, Zeshan You and Hongwei Shen
    Citation: Journal of Experimental & Clinical Cancer Research 2025 44:71
    Content type: Retraction Note Published on:

  34. Mutations in KRAS and BRAF genes are prevalent in colorectal cancer (CRC), which strikingly promote tumorigenesis and lead to poor response to a variety of treatments including immunotherapy by activating the MAP...

    Authors: Zhao Liu, Yiqi Li, Simeng Wang, Yubo Wang, Mengjun Sui, Jiaxin Liu, Pu Chen, Jianling Wang, Yuchen Zhang, Chengxue Dang and Peng Hou
    Citation: Journal of Experimental & Clinical Cancer Research 2025 44:70
    Content type: Research Published on:

  36. Sustaining proliferation signaling is the top hallmarks of cancer, driving continuous tumor growth and resistance to drug treatments. Blocking proliferation signaling has shown limited benefit in clinical trea...

    Authors: Zhengtao Hong, Xing Huang, Linghao Xia, Tingbo Liang and Xueli Bai
    Citation: Journal of Experimental & Clinical Cancer Research 2025 44:68
    Content type: Research Published on:

  37. Targeting oncogenic histone modification by histone deacetylase inhibitors (HDACis) demonstrates promising prospects in clinical cancer treatment, whereas a notable proportion of patients cannot benefit from H...

    Authors: Xutao Xu, Qianqian Wang, Ke Guo, Junjie Xu, Yunkun Lu, Huijuan Chen, Weilin Hu, Yilin Fu, Lu Sun, Ying He, Zhehang Chen, Wenhao Xia, Mengtian Pan, Beibei Lin, Wenjuan Yang, Qingqing Wang…
    Citation: Journal of Experimental & Clinical Cancer Research 2025 44:67
    Content type: Research Published on:

  39. Malignant mesothelioma (MM) is a rare and aggressive form of cancer that affects the mesothelial surfaces, associated with exposure to asbestos fibres. To date, no cure is available for MM and therapeutically ...

    Authors: Miriam Piccioni, Francesco Di Meo, Anna Valentino, Virginia Campani, Maddalena Arigoni, Mirella Tanori, Mariateresa Mancuso, Rossana Cuciniello, Marco Tomasetti, Federica Monaco, Gaia Goteri, Enrico P. Spugnini, Raffaele A. Calogero, Giuseppe De Rosa, Gianfranco Peluso, Alfonso Baldi…
    Citation: Journal of Experimental & Clinical Cancer Research 2025 44:65
    Content type: Research Published on:

  40. The invasive and metastatic spread of serous ovarian cancer (SOC) results from the cooperative interactions between cancer and stroma, which include extracellular matrix (ECM) and cellular components, includin...

    Authors: Ilenia Masi, Flavia Ottavi, Valentina Caprara, Danila Del Rio, Martina Kunkl, Francesca Spadaro, Valerio Licursi, Loretta Tuosto, Anna Bagnato and Laura Rosano’
    Citation: Journal of Experimental & Clinical Cancer Research 2025 44:64
    Content type: Research Published on:

  41. Bladder cancer (BLCA) ranks among the most prevalent malignancies of the urinary system, with its clinical diagnosis predominantly reliant on invasive procedures. Traditional chemotherapy regimens exhibit sign...

    Authors: Dexin Shen, Xiang Yu, Xuefeng Fan, Yu Liang, Dongmei Lu, Zongpan Ke, Lei Wang, Ping Xiang and Jun Xiao
    Citation: Journal of Experimental & Clinical Cancer Research 2025 44:63
    Content type: Research Published on:

  42. The ubiquitously expressed transmembrane protein, Herpesvirus Entry Mediator (HVEM), functions as a molecular switch, capable of both activating and inhibiting the immune response depending on its interacting ...

    Authors: Yuanshan Yao, Bin Li, Jing Wang, Chunji Chen, Wen Gao and Chunguang Li
    Citation: Journal of Experimental & Clinical Cancer Research 2025 44:62
    Content type: Research Published on:

  43. Brain metastasis (BrM) poses a significant challenge to the prognosis and quality of life for patients with non-small cell lung cancer (NSCLC). Gamma-aminobutyric acid (GABA), an inhibitory neurotransmitter in...

    Authors: Mengqing Xie, Hao Qin, Li Liu, Jing Wu, Zhikai Zhao, Yaodong Zhao, Yujia Fang, Xin Yu and Chunxia Su
    Citation: Journal of Experimental & Clinical Cancer Research 2025 44:61
    Content type: Research Published on:

  44. Crosstalk between pancreatic cancer cells and tumor-associated macrophages (TAMs) is a critical driver of malignant progression, and plays an important role in the low response rate to immunotherapy in patient...

    Authors: Shi Dong, Xin Li, Zhou Chen, Huaqing Shi, Zhengfeng Wang and Wence Zhou
    Citation: Journal of Experimental & Clinical Cancer Research 2025 44:60
    Content type: Research Published on:

  45. This article has been retracted. Please see the Retraction Notice for more detail: https://doiorg.publicaciones.saludcastillayleon.es/10.1186/s13046-024-03113-9.

    Authors: Guannan Shu, Zhang Zhao, Tianxin Zhao, Changmi Deng, Jiangquan Zhu, Yufeng Han, Minyu Chen, Jiajia Jing, Gaochen Bai, Dian Li, Feng Li, Jing He, Wen Fu and Guochang Liu
    Citation: Journal of Experimental & Clinical Cancer Research 2025 44:59
    Content type: Retraction Note Published on:

  46. Co-targeting of immune checkpoint inhibitors (ICI) CTLA-4 and PD-1 has recently become the new first-line standard of care therapy of pleural mesothelioma (PM) patients, with a significant improvement of overa...

    Authors: Maria Fortunata Lofiego, Rossella Tufano, Emma Bello, Laura Solmonese, Francesco Marzani, Francesca Piazzini, Fabrizio Celesti, Francesca Pia Caruso, Teresa Maria Rosaria Noviello, Roberta Mortarini, Andrea Anichini, Michele Ceccarelli, Luana Calabrò, Michele Maio, Sandra Coral, Anna Maria Di Giacomo…
    Citation: Journal of Experimental & Clinical Cancer Research 2025 44:58
    Content type: Research Published on:

  47. From 17 to 19th October 2024, the XXI Italian Network for Bio-Immunotherapy of Tumors Meeting (NIBIT) took place in Palermo, in the marvelous historical location of Teatro Politeama, under the auspices of the ...

    Authors: Beatrice Belmonte, Sheila Spada, Paola Allavena, Matteo Benelli, Vincenzo Bronte, Giulia Casorati, Lorenzo D’Ambrosio, Roberto Ferrara, Anna Mondino, Paola Nisticò, Roberta Sommaggio, Marcella Tazzari, Claudio Tripodo, Antonio Sica and Pier Francesco Ferrucci
    Citation: Journal of Experimental & Clinical Cancer Research 2025 44:57
    Content type: Meeting Report Published on:

  48. AZIN1 is a cell cycle regulator that is upregulated in a variety of cancers. AZIN1 overexpression can induce a more aggressive tumor phenotype via increased binding and resultant inhibition of antizyme. Antizy...

    Authors: Julie Sesen, Tyra Martinez, Sara Busatto, Larysa Poluben, Hassan Nassour, Caroline Stone, Karthik Ashok, Marsha A. Moses, Edward R. Smith and Aram Ghalali
    Citation: Journal of Experimental & Clinical Cancer Research 2025 44:56
    Content type: Research Published on:

  49. The triple-negative subtype of breast cancer is particularly challenging to treat due to its aggressiveness with a high risk of brain metastasis, and the lack of effective targeted therapies. Tubulin beta 2B c...

    Authors: Qingling He, Jianyang Hu, Fung-Yin Ngo, Huiqi Zhang, Lin He, Hao Huang, Tan Wu, Yilin Pan, Zihan Yang, Yuanyuan Jiang, William C. Cho, Wah Cheuk, Gary M. Tse, Julia Y. Tsang, Mengsu Yang, Liang Zhang…
    Citation: Journal of Experimental & Clinical Cancer Research 2025 44:55
    Content type: Research Published on:

  50. Immunotherapies targeting PD-1 and CTLA-4 are key components of the treatment of metastatic clear cell renal cell carcinoma (mccRCC). However, they have distinct safety profiles and resistance to treatment can...

    Authors: Ivan Pourmir, Nadine Benhamouda, Thi Tran, Hugo Roux, Joséphine Pineau, Alain Gey, Andyara Munoz, Nesrine Mabrouk, Nicolas Epaillard, Virginie Verkarre, Yann-Alexandre Vano, Eric Tartour and Stéphane Oudard
    Citation: Journal of Experimental & Clinical Cancer Research 2025 44:54
    Content type: Research Published on:

Annual Journal Metrics

  • Citation Impact 2023
    Journal Impact Factor: 11.4
    5-year Journal Impact Factor: 11.4
    Source Normalized Impact per Paper (SNIP): 1.770
    SCImago Journal Rank (SJR): 2.806

    Speed 2024
    Submission to first editorial decision (median days): 2
    Submission to acceptance (median days): 96

    Usage 2024
    Downloads: 4,059,655
    Altmetric mentions: 2,197

Journal of Experimental & Clinical Cancer Research

ISSN: 1756-9966

Contact us